Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miebo in Habitual Contact Lens Wearers
NCT06176651Phase 4Completed
- Sponsor
- Gordon Schanzlin New Vision Institute
- Start
- Sep 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of perfluorohexyloctane in dry eye disease (DED) (2 arms), sponsored by Gordon Schanzlin New Vision Institute. Primary endpoint: Safety of Miebo at 30 days. Started Sep 2023; status: completed.
02
Drugs
perfluorohexyloctane
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06176651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06176651.